Pediatric CAR-T Cell Therapy
NMPA-approved products · Extensive pediatric trial network
Typical Duration
Approx. 4–6 weeks
Estimated Cost
Est. USD 45,000–70,000
Reflects typical total program cost at national children's centers including cell processing, hospitalization and CRS management. Itemized written estimate provided after individual assessment.
Why China
Pediatric CAR-T Cell Therapy
The world's largest pediatric CAR-T ecosystem
China accounts for more than half of registered CAR-T studies worldwide, and its major children's hospitals run dedicated pediatric protocols — CD19, CD22 and dual-target products — unavailable in many home countries.
Dual-target & sequential strategies against relapse
Chinese centers pioneered CD19/CD22 dual-target and sequential CAR-T infusions that reduce antigen-escape relapse — a common cause of failure after single-target therapy in children.
Pediatric-specific safety protocols
Dedicated pediatric CRS (cytokine release syndrome) grading and rescue pathways, child-sized dosing and 24/7 pediatric ICU support make treatment safe even for small children.
A fraction of Western costs
Total program costs are typically one third of US pricing, with transparent packaged estimates provided before travel — no hidden markups.
Quick Overview
Products & targets
CD19, CD22 and dual-target pediatric CAR-T programs.
Pre-treatment assessment
Diagnosis, MRD status, prior lines and organ function review.
Process & timeline
Record review, apheresis, manufacturing, lymphodepletion, infusion.
Risks & follow-up
Managing CRS/ICANS and long-term monitoring for children.
Care Journey
Case Review
Submit your records and imaging; receive a written expert assessment and preliminary plan within 48 hours.
Plan & Estimate
A multidisciplinary team (MDT) defines your child's individualized plan with a transparent cost estimate.
Travel Preparation
We assist with medical visas, flights and accommodation, and assign a professional medical interpreter.
In-Hospital Care
A dedicated coordinator accompanies your family through examinations and treatment, bridging all communication.
Recovery & Follow-up
Remote follow-up after you return home, with review schedules and medication guidance.
Long-term Management
Stay connected with your child's treating team, with fast-track return visits whenever needed.
Medical Team
Hospitals
Beijing Children's Hospital, Capital Medical University
Beijing · National Children's Medical Center
Shanghai Children's Medical Center, SJTU
Shanghai · National Children's Medical Center
The Children's Hospital, Zhejiang University School of Medicine
Hangzhou · National Clinical Research Center for Child Health
Children's Hospital of Chongqing Medical University
Chongqing · National Children's Regional Medical Center
Specialists
Frequently Asked Questions
Is my child eligible for CAR-T in China?+
CAR-T is considered for children with relapsed or refractory B-cell leukemia/lymphoma, or as a bridge to transplant. Eligibility depends on diagnosis, CD19/CD22 expression, prior treatments and organ function. Submit your child's records for a free expert review — our team responds within 24–48 hours.
How much should a family budget?+
Total program costs typically run USD 45,000–70,000 including cell processing, lymphodepletion, hospitalization and CRS management — roughly one third of US pricing. Diagnostics, bridging therapy and extended ICU stays are quoted separately in a written estimate before you travel.
What are the main risks for children?+
Key risks are cytokine release syndrome (CRS), neurotoxicity (ICANS), infection and low blood counts. Pediatric centers use child-specific grading, early tocilizumab protocols and 24/7 PICU support; most children recover fully with appropriate monitoring.
How long must we stay in China?+
Plan for 4–6 weeks: evaluation and apheresis (week 1), cell manufacturing (2–3 weeks, during which bridging therapy may be given), lymphodepletion and infusion, then about 2 weeks of monitoring before travel fitness is assessed.
Can both parents stay with the child?+
Yes. Pediatric wards allow a parent to room-in throughout, and we arrange family accommodation, interpreting and daily support. A caregiver is essential — fever or changes in awareness after infusion must be reported immediately.
What if leukemia returns after CAR-T?+
Depending on the relapse mechanism, options include CAR-T against a second target (e.g., CD22), dual-target re-infusion, bispecific antibodies such as blinatumomab, or bridging to stem cell transplant. China's active pediatric trial network offers more later-line options than most countries.
Detailed Information
Pediatric CAR-T programs & targets
| Target | Strategy | Typical indication | Status in China |
|---|---|---|---|
| CD19 | Single-target CAR-T | Relapsed/refractory B-ALL, B-cell lymphoma | NMPA-approved products incl. pediatric indication (ages 3–21) |
| CD22 | Single-target CAR-T | CD19-negative or post-CD19 relapse B-ALL | Advanced clinical programs at national centers |
| CD19/CD22 | Dual-target or sequential | High-risk refractory B-ALL, antigen-escape prevention | Pediatric trial network |
| BCMA & others | Research protocols | Rare pediatric plasma-cell / Hodgkin indications | Clinical trials |
Program availability and eligibility must be confirmed by the treating center after record review.
Pre-treatment assessment
- Diagnosis confirmation: bone marrow studies, flow cytometry for CD19/CD22 expression, cytogenetics and fusion-gene panels.
- Disease status: MRD level, prior lines of therapy and response, transplant history.
- Fitness: organ function, active infection screening and performance status adapted for children.
- Records needed: pathology and marrow reports, treatment summaries, recent labs and imaging — we translate and format them for the hospital.
Treatment process & estimated timeline
- Week 1: record review on arrival, confirmatory tests, final eligibility sign-off.
- Week 1–2: leukapheresis (child-friendly collection with pediatric sedation when needed).
- Weeks 2–4: GMP cell manufacturing and release testing; bridging therapy as required.
- Week 4–5: fludarabine + cyclophosphamide lymphodepletion, then CAR-T infusion 1–3 days later.
- Weeks 5–6: monitored recovery focused on CRS/ICANS; fitness-to-fly assessment before returning home.
Recovery & long-term follow-up
- Blood counts, immunoglobulin levels and MRD monitored per center protocol, with immunoglobulin replacement when indicated.
- Infection prevention guidance and a deferred vaccination schedule reviewed with parents.
- After returning home, we establish joint follow-up with your local physicians and relay results back to the treating center remotely.
